Pyridine and pyrazine derivative for the treatment of chronic bronchitis
US11911371B2 · kind B2 · utility
0Cited by
105References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 2, 2021 |
| Grant date | Feb 27, 2024 |
| Priority date | — |
| Expiry date | Mar 4, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.